GHRH analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-16. Anything still debated is marked as such rather than presented as settled.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
==== Mental health ==== Estrogen is considered to play a significant role in women's mental health. Sudden estrogen withdrawal, fluctuating estrogen, and periods of sustained low estrogen levels correlate with a significant lowering of mood. Clinical recovery from postpartum, perimenopause, and postmenopause depression has been shown to be effective after levels of estrogen were stabilized and/or restored. Menstrual exacerbation (including menstrual psychosis) is typically triggered by low estrogen levels, and is often mistaken for premenstrual dysphoric disorder. Compulsions in male lab mice, such as those in obsessive-compulsive disorder (OCD), may be caused by low estrogen levels. When estrogen levels were raised through the increased activity of the enzyme aromatase in male lab mice, OCD rituals were dramatically decreased. Hypothalamic protein levels in the gene COMT are enhanced by increasing estrogen levels which are believed to return mice that displayed OCD rituals to normal activity. Aromatase deficiency is ultimately suspected which is involved in the synthesis of estrogen in humans and has therapeutic implications in humans having obsessive-compulsive disorder. Local application of estrogen in the rat hippocampus has been shown to inhibit the re-uptake of serotonin. Contrarily, local application of estrogen has been shown to block the ability of fluvoxamine to slow serotonin clearance, suggesting that the same pathways which are involved in SSRI efficacy may also be affected by components of local estrogen signaling pathways.
While the approaches above have shown success, they are inherently limited by their need for derivatization, which jeopardizes the affinity of the interaction that derivatized compounds are said to emulate and introduces steric hindrance. Immobilized ligands and targets are limited in their ability to move freely through space in a way that replicates the native protein-ligand interaction, and conformational change from induced fit is often limited when proteins or drugs are immobilized. Probe-based approaches also alter the three-dimensional nature of the ligand-protein interaction by introducing functional groups to the ligand, which can alter compound activity. Derivatization-free approaches aim to infer interactions by proxy, often through observations of changes to protein stability upon binding, and sometimes through chromatographic co-elution. The stability-based methods below are thought to work due to ligand-induced shifts in equilibrium concentrations of protein conformational states. A single protein type in solution may be represented by individual molecules in a variety of conformations, with many of them different from one another despite being identical in amino acid sequence. Upon binding a drug, the majority of ligand-bound protein enters an energetically favorable conformation, and moves away from the unpredictable distribution of less stable conformers. Thus, ligand binding is said to stabilize proteins, making them resistant to thermal, enzymatic and chemical degradation. Some examples of stability-based derivatization-free approaches follow.
== Structure and available forms == α-Bungarotoxin consists of an 8 kDa, single polypeptide chain that contains 74 amino acid residues. This polypeptide chain is cross-linked by five disulfide bridges, categorizing the α-bungarotoxin as a type II α-neurotoxin within the three-finger toxin family. These disulfide bridges are formed between the specific cysteine residues and are important for the stability and function of the toxin. Furthermore, α-bungarotoxin contains ten residues of half-cysteine per molecule. The specific arrangements of disulfide bridges formed by these cysteine residues result in the 11-ring structure within the toxin molecule. This 11-ring structure is particularly essential for the toxin interactions with the target receptors and modulation of the neurotransmission at the neuromuscular junction. The amino acid sequence of the α-bungarotoxin contains a high frequency of homodipeptides, with ten pairs present where serine and proline dipeptides occur twice in the sequence. The active site of the toxin is located in the region from position 24 to position 45 within the sequence. There are some key amino acids commonly found in this region that include cysteine, arginine, glycine, lysine and valine. As previously mentioned, cysteine is crucial for the disulfide bridges formation in proteins. Arginine and lysine can participate in interactions with negatively charged molecules or residues, so they may play a role in the binding to specific receptors or substrates. Glycine may contribute to the flexibility and conformational dynamics of the α-bungarotoxin.
== Medical uses == Etoperidone was used or was intended for use as an antidepressant in the treatment of depression. Etoperidone might be useful as a hallucinogen antidote or "trip killer" in blocking the effects of serotonergic psychedelics like psilocybin and lysergic acid diethylamide (LSD).
Sources: en.wikipedia.org
=== Hanging flowers in ventilated area === There are several air-drying methods used for different kinds of flowers. The easiest and most effective way to dry most flowers is to tie them in small bundles with twine, raffia or ribbons, and hang them upside down, out of direct sunlight in a warm, well-ventilated place. Bunches should contain one type of flower. Large flowers are dried individually. The leaves stripped as soon as possible after picking. They retain moisture and slow down the drying process. Wall hooks, poles or wires are placed at least 15 centimetres (6 in) from the ceiling. Heads should be staggered to allow plenty of air to circulate. This prevents mildew and rot. It may be necessary to re-tie bunches or individual flowers half way through the drying process, because the stems tend to shrink as they dry. The drying period can range from one week to several weeks depending on the type of material, when and where it was harvested and the humidity of the place where it is drying. The stems of hung flowers tend to dry unnaturally straight and the flowers become very brittle. Suggested flowers to air dry include: strawflowers, goldenrod, Hydrangeas, Celosia (crested and plumed types), globe amaranth, Salvia, Xeranthemum and many of the "everlastings."
"Novel Liquid Crystalline Compounds and Polymers,"J.S. Bradshaw, M.L. Lee, K.E. Markides, and B.A. Jones. US Patent Number 4,864,033. Filed: November 27, 1985. Issued: February 1989. "Multi-Element Selective Radio Frequency Plasma Detector for Capillary Gas Chromatography, F. Yang, P. Farnsworth, R. Skelton, K.E. Markides, and M.L. Lee. U.S. Patent Application Serial No. 24,095. Filed: March 12, 1987. Issued: January 25, 1989. "Oligoethylene Oxide Substituted Siloxane Compounds and Polymers," J.S. Bradshaw, M.L. Lee, K.E. Markides, Filed: December, 1987. "Chiral Polysiloxane Compounds and Polymers," J.S. Bradshaw, M.L. Lee, K.E. Markides, Filed: January, 1988. Issued: June 1990. "Chromatographic Arylcarboxamide Polysiloxanes," J.S. Bradshaw, M.L. Lee, K.E. Markides, Filed: June, 1988. Issued: March 1990. "Novel Chiral Copolymers with Oligosiloxane Spacers," J.S. Bradshaw, B.E. Rossiter, B.J. Tarbet, D.F. Johnson, M.L. Lee, K.E. Markides, File No. 9393 CIP. Filed: March 1992. “Encapsulated Nanoparticles for Drug Delivery”, G. Jacobson, R.N. Zare, K.E. Markides, R.R. Shinde and C.H. Contag, File No. 11/748,408, Filed: May 14, 2007.
William de la Founte, a wealthy Bristol merchant has been identified as the first recorded English slave traders. Of Gascon origin, in 1480 he was one of the four venturers granted a licence "to trade in any parts". Renewed growth came with the 17th-century rise of England's American colonies and the rapid 18th-century expansion of Bristol's part in the "Triangular trade" in Africans taken for slavery in the Americas. Over 2000 slaving voyages were made by Bristol ships between the late 17th century and abolition in 1807, carrying an estimated half a million people from Africa to the Americas in brutal conditions. Average profits per voyage were seventy per cent and more than fifteen per cent of the Africans transported died or were murdered on the Middle Passage. Some slaves were brought to Bristol, from the Caribbean; notable among these were Scipio Africanus, buried at Henbury and Pero Jones brought to Bristol by slave trader and plantation owner John Pinney. The slave trade and the consequent demand for cheap brass ware for export to Africa caused a boom in the copper and brass manufacturing industries of the Avon valley, which in turn encouraged the progress of the Industrial Revolution in the area. Prominent manufacturers such as Abraham Darby and William Champion developed extensive works between Conham and Keynsham which used ores from the Mendips and coal from the North Somerset coalfield. Water power from tributaries of the Avon drove the hammers in the brass batteries, until the development of steam power in the later 18th century.
Additional design elements are common among contemporary In-N-Out locations. Matching In-N-Out's California-inspired palm tree theme, palm trees are sometimes planted to form an "X" in front of the restaurants. This is an allusion to founder Harry Snyder's favorite movie, Stanley Kramer's It's a Mad, Mad, Mad, Mad World, in which the characters look for a hidden treasure and find it under "the big W" made by four palm trees, with the middle two forming an "X".
Before receiving his permanent prison assignment, Noriega was placed in the Federal Detention Center, Miami. Noriega was incarcerated in the Federal Correctional Institution, Miami. Under Article 85 of the Third Geneva Convention, Noriega was considered a prisoner of war, despite his conviction for acts committed prior to his capture by the "detaining power" (the U.S.). This status meant that he had his own prison cell, furnished with electronics and exercise equipment. His cell was nicknamed "the presidential suite". While Noriega was in prison, he was visited regularly over two years by two evangelical Christian ministers, Clift Brannon and Rudy Hernandez. Noriega, nominally a Roman Catholic, was reported to have undergone a conversion to evangelical Christianity in May 1990, and was baptized in October 1992, while still in prison. Noriega's prison sentence was reduced from 40 to 30 years by the judge, then to 17 years for good behavior. His U.S. sentence thus ended on September 9, 2007, though his incarceration ended up being extended while extradition requests by other countries were being adjudicated.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.